Replies to post #181135 on Biotech Values

[DewDiligence]

Clearly a low-probability trial, which is why PFE offloaded the expense of running it.

[jq1234]

ARIA: Looks like Cortez gave up 30mg for 1st line CML chronic phase, trying accelerated phase now:

The goal of this clinical research study is to learn if ponatinib can help to control CML in accelerated phase.

Inclusion Criteria:

Diagnosis of Ph-positive (by cytogenetics or FISH) or Bcr-ABL-positive (by PCR) CML with accelerated phase features at the time of diagnosis.

http://clinicaltrials.gov/show/NCT01570868